As expected, RBM4 depletion-induced senescence could be partially reversed by inhibition of SERPINE1 with tiplaxtinin (a SERPINE1 inhibitor) in lung cancer cells, as judged by SA-β-gal activity (Fig. 5C, D). Here, RBM4 is linked to lung cancer.